PanTera

PanTeraPanTera
PanTera

PanTera

Focuses on producing actinium-225, a rare radioisotope used in targeted alpha therapies for cancer.

Website
DR 38Speed 702022Active58Mol, Belgium
Rate
Advertise here

About

PanTera is a Belgian company focused on the large-scale, reliable production of Actinium-225 (Ac-225), a scarce radioisotope critical for emerging targeted alpha therapies in cancer treatment. They are constructing a state-of-the-art production facility in Mol, Belgium, utilizing a proprietary process to transform Radium-226 into high-purity Ac-225.
Frequently asked

What does PanTera do?

PanTera is a Belgian company focused on the large-scale, reliable production of Actinium-225 (Ac-225), a scarce radioisotope critical for emerging targeted alpha therapies in cancer treatment. They are constructing a state-of-the-art production facility in Mol, Belgium, utilizing a proprietary process to transform Radium-226 into high-purity Ac-225.

What is PanTera's valuation?

StartupHub estimates PanTera's effective valuation at $499.0M (range $304.3M to $730.2M, 11% confidence), based on comparable companies in the sector.

How much funding has PanTera raised?

PanTera has raised a total of $122M in funding. The most recent round on record is Series A.

Where is PanTera headquartered?

PanTera is headquartered in Mol, Belgium.

When was PanTera founded?

PanTera was founded in 2022.

How many employees does PanTera have?

PanTera has approximately 58 people on record.

HEADCOUNT
58
DOMAIN RATING
38
Comments

No comments yet. Be the first to share your take.